Aardvark Therapeutics Inc AARD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
-
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
-
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
-
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
-
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Trading Information
- Previous Close Price
- $5.00
- Day Range
- $5.03–7.92
- 52-Week Range
- $3.35–17.94
- Bid/Ask
- $7.65 / $7.66
- Shares Outstanding
- 21.82M
- Market Cap
- $165.80M
- Volume/Avg
- 4M / 259,452
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 40
Valuation
|
Metric
|
AARD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AARD
|
|---|---|
Quick Ratio | 7.86 |
Current Ratio | 8.06 |
Interest Coverage | — |
Quick Ratio
AARD
Profitability
|
Metric
|
AARD
|
|---|---|
Return on Assets (Normalized) | −49.08% |
Return on Equity (Normalized) | −53.14% |
Return on Invested Capital (Normalized) | −56.90% |
Return on Assets
AARD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^G>jx& | LOCK|!$#r# | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|nV<qP% | LOCK|r>^%! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&&T<&lD | LOCK|Cqr | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>WxcM?H | LOCK|#L@Z^ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xbDgfn | LOCK|Wx | $36B | |||
| Moderna Inc
MRNA
| LOCK|%Fvg@> | LOCK|J<H | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|DSWB!&Sy | LOCK|C&y?$ | $25B | |||
| Incyte Corp
INCY
| LOCK|d$>%#X | LOCK|jzF | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%gNh$?R | LOCK|l>> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<##!kyH | LOCK|S$ | $17B |
United States